Funding Opportunity PA-18-314 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products, and services that benefit society. Toward meeting this objective, the I-Corps program is being offered. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will continue providing administrative supplement awards to currently-funded SBIR and STTR Phase I grantees.

Funding Opportunity PAR-18-313 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. For the purpose of this FOA, cancers derived from the same organ system (i.e., a group of organs that perform a common function) are considered related. Examples of such organ systems include gastrointestinal, endocrine and other biological systems. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers sustained and promoted by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

Notice NOT-HL-17-544 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-317 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Funding Opportunity PAR-18-310 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Notice NOT-MH-18-001 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-005 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-006 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-005 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-004 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-003 from the NIH Guide for Grants and Contracts

Notice NOT-OH-18-001 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-004 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-003 from the NIH Guide for Grants and Contracts

Notice NOT-GM-18-001 from the NIH Guide for Grants and Contracts

Build document clustering, topic analysis, text classification, named entity recognition, sentiment analysis, and part-of-speech tagging methods for...
From KPMG LLP - Wed, 11 Oct 2017 08:28:44 GMT - View all Atlanta, GA jobs

Perform machine learning, natural language, and statistical analysis methods, such as classification, collaborative filtering, association rules, sentiment...
From KPMG LLP - Wed, 11 Oct 2017 08:28:40 GMT - View all Atlanta, GA jobs

Notice NOT-FD-18-002 from the NIH Guide for Grants and Contracts

To apply, please submit a letter of application describing research interests and professional goals, as well as a CV and contact information for three...
From Penn State University - Tue, 10 Oct 2017 18:00:19 GMT - View all University Park, PA jobs

Funding Opportunity RFA-CA-17-046 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.